Compare MKTW & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKTW | GRDX |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 39.3M |
| IPO Year | 2020 | N/A |
| Metric | MKTW | GRDX |
|---|---|---|
| Price | $17.14 | $4.46 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 11.1K | ★ 123.5K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 10.20% | N/A |
| EPS Growth | ★ 1183.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $512,403,000.00 | N/A |
| Revenue This Year | $1.52 | N/A |
| Revenue Next Year | $4.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.49 | $1.87 |
| 52 Week High | $21.74 | $6.93 |
| Indicator | MKTW | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 44.89 |
| Support Level | $16.17 | $2.16 |
| Resistance Level | $17.60 | $5.30 |
| Average True Range (ATR) | 0.53 | 0.64 |
| MACD | 0.01 | -0.25 |
| Stochastic Oscillator | 57.58 | 4.78 |
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.